{"id":"abilify-maintena","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Akathisia"},{"rate":"5-10","effect":"Tremor"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Anxiety"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5-10","effect":"Injection site pain"}]},"_chembl":{"chemblId":"CHEMBL1112","moleculeType":"Small molecule","molecularWeight":"448.39"},"_dailymed":{"setId":"ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6","title":"ABILIFY MAINTENA (ARIPIPRAZOLE) KIT [OTSUKA AMERICA PHARMACEUTICAL, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole functions as a partial agonist at dopamine D2 receptors, which helps stabilize dopamine neurotransmission in the brain. The Maintena formulation uses microsphere technology to provide sustained drug release over 4 weeks, improving medication adherence in patients with psychotic disorders. This mechanism reduces both positive symptoms (hallucinations, delusions) and negative symptoms of schizophrenia and mania in bipolar disorder.","oneSentence":"Abilify Maintena is a long-acting intramuscular injection of aripiprazole that acts as a dopamine D2 receptor partial agonist to treat schizophrenia and bipolar disorder.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:37.373Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia (maintenance treatment)"},{"name":"Bipolar I disorder (maintenance treatment of acute manic and mixed episodes)"}]},"trialDetails":[{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT00288353","phase":"PHASE3","title":"Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2006-01","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":48},{"nctId":"NCT05545891","phase":"PHASE2","title":"Aripiprazole in Body Focused Repetitive Behaviors","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06","conditions":"Trichotillomania (Hair-Pulling Disorder), Dermatillomania","enrollment":100},{"nctId":"NCT01490086","phase":"PHASE2","title":"RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Reviva Pharmaceuticals","startDate":"2011-12","conditions":"Acute Schizophrenia, Schizoaffective Disorder","enrollment":234},{"nctId":"NCT05169268","phase":"","title":"Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-02-01","conditions":"Schizophrenia and Related Disorders, Anxiety Depression","enrollment":10},{"nctId":"NCT04812379","phase":"","title":"Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2021-04-07","conditions":"Bipolar Disorder I","enrollment":535},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT05322031","phase":"PHASE4","title":"The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia","status":"COMPLETED","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2022-08-01","conditions":"Schizophrenia, Myelin Degeneration, Cognition Disorder","enrollment":15},{"nctId":"NCT05531591","phase":"PHASE4","title":"RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2019-08-01","conditions":"Depression, Dementia, Mild Cognitive Impairment","enrollment":87},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT02960763","phase":"PHASE4","title":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-02-24","conditions":"Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression","enrollment":742},{"nctId":"NCT02918370","phase":"PHASE3","title":"Aripiprazole for Bipolar Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-11","conditions":"Bipolar Disorder, Alcoholism, Alcohol Abuse","enrollment":75},{"nctId":"NCT03423680","phase":"PHASE3","title":"A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression","status":"RECRUITING","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2018-02-22","conditions":"Depression, Bipolar","enrollment":390},{"nctId":"NCT06372210","phase":"NA","title":"A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2023-06-26","conditions":"Mental Disorder, Schizophrenia, Major Depressive Disorder","enrollment":54},{"nctId":"NCT03522168","phase":"","title":"Long-term Antipsychotic Pediatric Safety Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-01-10","conditions":"Weight, Body","enrollment":509},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT05554627","phase":"PHASE4","title":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2023-10-27","conditions":"Depressive Disorder, Major","enrollment":""},{"nctId":"NCT04203056","phase":"PHASE4","title":"Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2019-12-16","conditions":"Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder","enrollment":15},{"nctId":"NCT02357849","phase":"PHASE4","title":"Fluoxetine vs Aripiprazole Comparative Trial (FACT)","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2014-07","conditions":"Attenuated Psychosis Syndrome","enrollment":9},{"nctId":"NCT05974241","phase":"PHASE4","title":"Irritability in Children With ADHD and Emotion Dysregulation","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2017-04-21","conditions":"Irritable Mood, ADHD","enrollment":36},{"nctId":"NCT00261443","phase":"PHASE4","title":"A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-09","conditions":"Bipolar Disorder","enrollment":1270},{"nctId":"NCT05804721","phase":"PHASE1","title":"Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-10-10","conditions":"Healthy","enrollment":29},{"nctId":"NCT03919994","phase":"","title":"Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2019-03-28","conditions":"Schizophrenia","enrollment":338},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT01354353","phase":"PHASE1","title":"A Study of Safety and Tolerability in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT05532254","phase":"PHASE1","title":"Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2021-02-14","conditions":"Healthy Subjects","enrollment":31},{"nctId":"NCT00276978","phase":"PHASE3","title":"Aripiprazole Augmentation Therapy in Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"University Hospital Freiburg","startDate":"2005-06","conditions":"Therapy-resistant Depression","enrollment":""},{"nctId":"NCT02977299","phase":"PHASE4","title":"Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-05-01","conditions":"Treatment Resistant Major Depressive Disorder","enrollment":278},{"nctId":"NCT00484471","phase":"PHASE4","title":"ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness","status":"COMPLETED","sponsor":"Korea Otsuka International Asia Arab","startDate":"2007-10","conditions":"Bipolar Disorder","enrollment":127},{"nctId":"NCT03408873","phase":"PHASE4","title":"CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)","status":"COMPLETED","sponsor":"Martha Sajatovic","startDate":"2018-04-01","conditions":"Bipolar Disorder, Medication Adherence, Medication Non Adherence","enrollment":30},{"nctId":"NCT03386851","phase":"","title":"Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2016-12-13","conditions":"Schizophrenia, Bipolar 1 Disorder","enrollment":1030},{"nctId":"NCT00468130","phase":"NA","title":"Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2006-05","conditions":"Autism","enrollment":13},{"nctId":"NCT03376763","phase":"PHASE4","title":"MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2017-11-21","conditions":"Schizophrenia, Antipsychotics, Long-Acting Injection","enrollment":201},{"nctId":"NCT02091882","phase":"PHASE4","title":"Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-03-21","conditions":"Device Latency","enrollment":30},{"nctId":"NCT01418339","phase":"PHASE3","title":"Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-07-27","conditions":"Tourette's Disorder","enrollment":135},{"nctId":"NCT01418352","phase":"PHASE3","title":"Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-08-02","conditions":"Tourette's Disorder","enrollment":83},{"nctId":"NCT01416441","phase":"PHASE3","title":"Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10-19","conditions":"Tourette's Disorder","enrollment":170},{"nctId":"NCT03892889","phase":"PHASE3","title":"A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-04-29","conditions":"Schizophrenia","enrollment":277},{"nctId":"NCT02339844","phase":"PHASE4","title":"Pan European Collaboration on Antipsychotic Naïve Schizophrenia II","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2014-01","conditions":"Schizophrenia","enrollment":130},{"nctId":"NCT03839251","phase":"PHASE4","title":"Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2018-06-01","conditions":"Schizophrenia","enrollment":82},{"nctId":"NCT03487783","phase":"PHASE3","title":"Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2018-05-02","conditions":"Tourette Syndrome","enrollment":121},{"nctId":"NCT03487770","phase":"PHASE3","title":"Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2018-04-09","conditions":"Autistic Disorder","enrollment":111},{"nctId":"NCT03287505","phase":"PHASE1","title":"Aripiprazole IM Depot for Chinese Patients With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2017-06-23","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT02146547","phase":"PHASE4","title":"European Long-acting Antipsychotics in Schizophrenia Trial","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-02","conditions":"Schizophrenia","enrollment":536},{"nctId":"NCT00895921","phase":"PHASE4","title":"Examining the Effects of Antipsychotic Medications on Insulin Sensitivity","status":"COMPLETED","sponsor":"Veterans Medical Research Foundation","startDate":"2008-11","conditions":"Diabetes","enrollment":30},{"nctId":"NCT00712270","phase":"PHASE4","title":"Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia","status":"TERMINATED","sponsor":"Kettering Health Network","startDate":"2005-04","conditions":"Schizophrenia","enrollment":21},{"nctId":"NCT03285503","phase":"PHASE1","title":"PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2018-08-17","conditions":"Schizophrenia","enrollment":12},{"nctId":"NCT01446328","phase":"PHASE4","title":"Bergen Psychosis Project 2 - The Best Intro Study","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2011-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":151},{"nctId":"NCT00279409","phase":"PHASE2","title":"Treatment of Children With ADHD Who do Not Fully Respond to Stimulants","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2006-07","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":10},{"nctId":"NCT03881449","phase":"PHASE4","title":"DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole","status":"UNKNOWN","sponsor":"Durham VA Medical Center","startDate":"2019-04-04","conditions":"Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder","enrollment":46},{"nctId":"NCT02574741","phase":"PHASE2","title":"Combination Treatment for Augmenting Language in Children With ASD","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2012-06","conditions":"Autism Spectrum Disorder","enrollment":58},{"nctId":"NCT01913327","phase":"PHASE4","title":"Antipsychotic Effects on Brain Function in Schizophrenia","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2013-04","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":4},{"nctId":"NCT02717130","phase":"NA","title":"Aripiprazole, Abilify Maintena Collaborative Clinical Protocol","status":"TERMINATED","sponsor":"Florida Atlantic University","startDate":"2016-06-08","conditions":"Schizophrenia","enrollment":9},{"nctId":"NCT02532491","phase":"PHASE4","title":"Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2014-05","conditions":"Schizophrenia, Psychotic Disorders","enrollment":200},{"nctId":"NCT03883204","phase":"PHASE4","title":"Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2015-01-01","conditions":"Schizophrenia, Psychotic Disorders, Psychosis","enrollment":115},{"nctId":"NCT00746252","phase":"NA","title":"Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2008-06","conditions":"Bipolar Disorder","enrollment":5},{"nctId":"NCT03643159","phase":"PHASE4","title":"A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-06-28","conditions":"Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder","enrollment":2},{"nctId":"NCT01338298","phase":"NA","title":"Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-01","conditions":"Hyperprolactinemia","enrollment":60},{"nctId":"NCT00288366","phase":"NA","title":"Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2006-01","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":49},{"nctId":"NCT03090503","phase":"PHASE4","title":"Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2014-06","conditions":"Schizophrenia, Psychotic Disorders, Psychosis","enrollment":200},{"nctId":"NCT01942187","phase":"PHASE4","title":"A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2013-08","conditions":"Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder Not Otherwise Specified (NOS)","enrollment":""},{"nctId":"NCT02472652","phase":"PHASE4","title":"Aripiprazole, Abilify Maintena Collaborative Clinical Protocol","status":"TERMINATED","sponsor":"Gazda, Thomas D., M.D., PC","startDate":"2015-06","conditions":"Sexual Dysfunction","enrollment":2},{"nctId":"NCT01696617","phase":"PHASE4","title":"Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2012-02-10","conditions":"Major Depressive Disorder","enrollment":46},{"nctId":"NCT00198107","phase":"PHASE3","title":"Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism","status":"COMPLETED","sponsor":"Indiana University","startDate":"2005-09","conditions":"Autistic Disorder","enrollment":81},{"nctId":"NCT01795105","phase":"","title":"ABF Tourette's Disorder Post Marketing Surveillance Study","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-06","conditions":"Tourette's Disorder","enrollment":692},{"nctId":"NCT02697045","phase":"PHASE4","title":"Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch","status":"COMPLETED","sponsor":"Abdi İbrahim Otsuka","startDate":"2017-01-04","conditions":"Schizophrenia","enrollment":23},{"nctId":"NCT00870727","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders","status":"COMPLETED","sponsor":"Indiana University","startDate":"2009-02","conditions":"Pervasive Developmental Disorder","enrollment":33},{"nctId":"NCT01333072","phase":"PHASE4","title":"Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2011-07","conditions":"Autistic Disorder","enrollment":80},{"nctId":"NCT00208533","phase":"PHASE2","title":"Aripiprazole in Children With Autism: A Pilot Study","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2004-02","conditions":"Autism","enrollment":11},{"nctId":"NCT00330863","phase":"PHASE4","title":"Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2006-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":357},{"nctId":"NCT00205699","phase":"PHASE4","title":"Metabolic Effects of Antipsychotics in Children","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2006-04","conditions":"Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder","enrollment":144},{"nctId":"NCT03150771","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-06-14","conditions":"Schizophrenia","enrollment":36},{"nctId":"NCT01655706","phase":"PHASE3","title":"Canadian Biomarker Integration Network for Depression Study","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2012-04-23","conditions":"Major Depressive Disorder","enrollment":211},{"nctId":"NCT00953745","phase":"NA","title":"Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":43},{"nctId":"NCT03358277","phase":"NA","title":"Aripiprazole Added on for DMDD in Youths With ADHD","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2014-11-19","conditions":"Disruptive Mood Dysregulation Disorder","enrollment":58},{"nctId":"NCT00665444","phase":"NA","title":"Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2008-04","conditions":"Bipolar Disorder, Metabolic Syndrome","enrollment":3},{"nctId":"NCT01292057","phase":"PHASE3","title":"Aripiprazole Effects on Alcohol Drinking and Craving","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2011-02","conditions":"Alcohol Dependence","enrollment":99},{"nctId":"NCT03232710","phase":"NA","title":"Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition","status":"UNKNOWN","sponsor":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","startDate":"2017-06-26","conditions":"Bioequivalence","enrollment":66},{"nctId":"NCT00683852","phase":"PHASE3","title":"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-09","conditions":"Major Depressive Disorder","enrollment":225},{"nctId":"NCT00250705","phase":"PHASE4","title":"Trial of Aripiprazole in the Treatment of CD in Adolescents","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2004-11-17","conditions":"Conduct Disorder","enrollment":12},{"nctId":"NCT01942148","phase":"PHASE3","title":"A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-08","conditions":"Schizophrenia","enrollment":68},{"nctId":"NCT00194012","phase":"PHASE3","title":"Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2004-08","conditions":"Bipolar Disorder","enrollment":62},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT00420459","phase":"PHASE2","title":"A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2007-04","conditions":"Fragile X Syndrome","enrollment":12},{"nctId":"NCT00276874","phase":"PHASE1","title":"Aripiprazole to Reduce Cocaine Relapse","status":"COMPLETED","sponsor":"Craig Rush","startDate":"2006-01","conditions":"Cocaine-Related Disorders","enrollment":41},{"nctId":"NCT01795547","phase":"PHASE3","title":"Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-02","conditions":"Schizophrenia","enrollment":295},{"nctId":"NCT01959035","phase":"PHASE3","title":"Aripiprazole Once-monthly in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-10","conditions":"Schizophrenia","enrollment":88},{"nctId":"NCT02526030","phase":"PHASE4","title":"Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2008-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":203},{"nctId":"NCT02305823","phase":"PHASE4","title":"Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2005-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":203},{"nctId":"NCT02534363","phase":"PHASE4","title":"Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2005-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":136},{"nctId":"NCT02131415","phase":"","title":"Real Life Assessment of Abilify Maintena","status":"TERMINATED","sponsor":"Lundbeck Canada Inc.","startDate":"2014-05","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT00308074","phase":"PHASE2","title":"An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders","status":"COMPLETED","sponsor":"Cambridge Health Alliance","startDate":"2006-02","conditions":"Autism, Asperger's Disorder, Pervasive Developmental Disorder","enrollment":14},{"nctId":"NCT00423878","phase":"PHASE4","title":"Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2007-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":215},{"nctId":"NCT00320671","phase":"PHASE4","title":"Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2005-12","conditions":"Schizophrenia","enrollment":198},{"nctId":"NCT00531518","phase":"NA","title":"Early Detection and Intervention for the Prevention of Psychosis","status":"COMPLETED","sponsor":"MaineHealth","startDate":"2007-10","conditions":"Schizophrenia, Bipolar Disorder, Depression","enrollment":292},{"nctId":"NCT02192723","phase":"NA","title":"A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2012-06","conditions":"Schizophrenia","enrollment":550},{"nctId":"NCT02334904","phase":"","title":"Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2014-07","conditions":"First-Episode Psychosis, Bipolar Disorder","enrollment":60},{"nctId":"NCT00220636","phase":"PHASE4","title":"Abilify as an Adjunctive Treatment for Refractory Depression","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2005-03","conditions":"Depressive Disorder, Major","enrollment":15},{"nctId":"NCT01154829","phase":"NA","title":"Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2008-12","conditions":"Schizophrenia","enrollment":136}],"_emaApprovals":[],"_faersSignals":[{"count":966,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":853,"reaction":"OFF LABEL USE"},{"count":834,"reaction":"DRUG INEFFECTIVE"},{"count":633,"reaction":"WEIGHT INCREASED"},{"count":532,"reaction":"NO ADVERSE EVENT"},{"count":488,"reaction":"PSYCHOTIC DISORDER"},{"count":484,"reaction":"ANXIETY"},{"count":475,"reaction":"SCHIZOPHRENIA"},{"count":416,"reaction":"TREATMENT NONCOMPLIANCE"},{"count":397,"reaction":"UNDERDOSE"}],"_approvalHistory":[{"date":"20150105","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20141205","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20140815","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20250122","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20250312","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20200205","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20170223","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20160115","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20150729","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20140929","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20140530","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20250328","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20130228","type":"ORIG","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20260128","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20170727","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20160818","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"},{"date":"20160324","type":"SUPPL","sponsor":"OTSUKA PHARM CO LTD","applicationNumber":"NDA202971"}],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aripiprazole","long-acting injectable aripiprazole","aripiprazole"],"phase":"marketed","status":"active","brandName":"Abilify Maintena","genericName":"Abilify Maintena","companyName":"Gazda, Thomas D., M.D., PC","companyId":"gazda-thomas-d-m-d-pc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abilify Maintena is a long-acting injectable antipsychotic that blocks dopamine D2 receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia (maintenance treatment), Bipolar I disorder (maintenance treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}